160 related articles for article (PubMed ID: 25540788)
1. Application of joinpoint regression in determining breast cancer incidence rate change points by age and tumor characteristics in women aged 30-69 (years) and in Isfahan city from 2001 to 2010.
Dehkordi ZF; Tazhibi M; Babazade S
J Educ Health Promot; 2014; 3():115. PubMed ID: 25540788
[TBL] [Abstract][Full Text] [Related]
2. Trends in breast cancer incidence rates by age and tumor characteristics of women in the city of Isfahan for the period 2001-2010: An application of joinpoint analysis.
Tazhibi M; Dehkordi ZF; Babazadeh S
J Res Med Sci; 2014 Apr; 19(4):319-25. PubMed ID: 25097604
[TBL] [Abstract][Full Text] [Related]
3. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
Jemal A; Ward E; Thun MJ
Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Incidence Trends in Isfahan Province Compared with those in England over the Period 2001-2013.
Ainvand MH; Shakibaei N; Ravankhah Z; Yadegarfar G
Int J Prev Med; 2021; 12():54. PubMed ID: 34447496
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the age trends in patients with breast cancer and different sizes of tumors in Breast Cancer Research Center of Isfahan University of Medical Sciences in 2001-2010.
Tazhibi M; Dehkordi ZF; Babazadeh S; Tabatabaeian M; Rezaei P; Faghihi M
J Educ Health Promot; 2014; 3():41. PubMed ID: 25013834
[TBL] [Abstract][Full Text] [Related]
6. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.
Hausauer AK; Keegan TH; Chang ET; Clarke CA
Breast Cancer Res; 2007; 9(6):R90. PubMed ID: 18162138
[TBL] [Abstract][Full Text] [Related]
7. Trend of breast cancer mortality in Montenegro, 1990-2018 - Joinpoint regression.
Vuković MMN; Laušević DB; Vućković LM; Bukumirić ZM
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3849-3857. PubMed ID: 35731054
[TBL] [Abstract][Full Text] [Related]
8. A rapid rise in hormone receptor-positive and HER2-positive breast cancer subtypes in Southern Thai women: A population-based study in Songkhla.
Chuaychai A; Sriplung H
PLoS One; 2022; 17(3):e0265417. PubMed ID: 35344552
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer Trend in Iran from 2000 to 2009 and Prediction till 2020 using a Trend Analysis Method.
Zahmatkesh B; Keramat A; Alavi N; Khosravi A; Kousha A; Motlagh AG; Darman M; Partovipour E; Chaman R
Asian Pac J Cancer Prev; 2016; 17(3):1493-8. PubMed ID: 27039796
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancer in West Virginia.
Abraham J; Flanagan M; Hazard H; Jubelirer S; Tirona MT; Vona-Davis L
W V Med J; 2009 Oct; 105 Spec No():54-9. PubMed ID: 19999267
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer incidence and hormone replacement therapy in Canada.
De P; Neutel CI; Olivotto I; Morrison H
J Natl Cancer Inst; 2010 Oct; 102(19):1489-95. PubMed ID: 20864685
[TBL] [Abstract][Full Text] [Related]
12. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
[TBL] [Abstract][Full Text] [Related]
14. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
15. [Breast cancer in México: a 10-year trend analysis on incidence and age at diagnosis].
Salinas-Martínez AM; Juárez-Ruiz A; Mathiew-Quirós Á; Guzmán-De la Garza FJ; Santos-Lartigue A; Escobar-Moreno C
Rev Invest Clin; 2014; 66(3):210-7. PubMed ID: 25695236
[TBL] [Abstract][Full Text] [Related]
16. Determining Prognostic Factors of Disease-Free Survival in Breast Cancer Using Censored Quantile Regression.
Yazdani A; Haghighat S
Breast Cancer (Auckl); 2022; 16():11782234221108058. PubMed ID: 35795199
[TBL] [Abstract][Full Text] [Related]
17. Relationship between breastfeeding factors and breast cancer in women referred to Seyed Al-Shohada Hospital in Isfahan, Iran.
Jafari-Mehdiabad F; Savabi-Esfahani M; Mokaryan F; Kazemi A
Iran J Nurs Midwifery Res; 2016; 21(6):622-627. PubMed ID: 28194204
[TBL] [Abstract][Full Text] [Related]
18. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
19. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
20. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.
Neuhouser ML; Aragaki AK; Prentice RL; Manson JE; Chlebowski R; Carty CL; Ochs-Balcom HM; Thomson CA; Caan BJ; Tinker LF; Urrutia RP; Knudtson J; Anderson GL
JAMA Oncol; 2015 Aug; 1(5):611-21. PubMed ID: 26182172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
